Viking’s Crash, Orforglipron’s Big Win, Wegovy vs Tirzepatide, Saxenda Generic & More
In this week’s Obesity Updates, we spotlight pivotal developments reshaping the global obesity treatment landscape — from clinical breakthroughs and regulatory milestones to strategic global expansions.
🔬 Key Highlights This Week:
💊 Orforglipron hits Phase 3 goal — up to 10.5% weight loss, with 46% losing at least 10%
❤️ Wegovy cuts heart risk by 57% vs tirzepatide in real-world data
🧪 Teva wins FDA approval for the first generic Saxenda
🧬 Novo Nordisk + Replicate BioScience partner on srRNA obesity therapies
🇮🇳 Novo & Apollo Clinics launch national obesity care program in India
🇨🇳 Lilly & JD Health expand DTC access for obesity and chronic care drugs in China
Whether you’re in biotech, healthcare, or public health, these insights deliver a rapid pulse on obesity innovation and strategy.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on obesity, weight loss therapies, and metabolic health
#ObesityUpdates #GLP1 #Wegovy #Orforglipron #Saxenda #Semaglutide #Tirzepatide #LucidQuest #ClinicalTrials #srRNA #TevaPharma #NovoNordisk #JDHealth #ApolloClinics #ObesityTreatment #MetabolicHealth #HealthcareStrategy #WeightLossDrugs